January 2013

Links Newsletter

The latest news, service information, tips and industry insight and from our staff of professionals at ACM Medical Laboratory

ACM Information Systems Moves Forward with Major Technology Investments

David Jachimiak, Chief Information Officer

ACM Medical Laboratory is pleased to report progress with several major information technology programs. Last year ACM implemented the first phase of enhanced web-based reporting with ACM QuikReport. ACM will soon launch a second phase that will continue to build on our earlier success by making access and reporting faster and easier with an array of enhanced features and on-demand daily reporting.

ACM is planning a launch of a redesigned web-access laboratory test reference manual. The new on-line system will have an improved user front-end and an advanced search capability putting access to all relevant specific information regarding ACM tests at the customer's fingertips.

Also, we are making solid progress with our enterprise Clinical Trials (CT) Management System upgrade. The new system from LabWare will replace the current legacy CT systems, provide greatly enhanced functionality and fully integrate ACM global clinical trials operations on one platform for all studies world-wide. These advances all contribute to ACM's growth and leadership and commitment to efficiency and quality customer service.

Please Welcome
David Jachimiak
Chief Information Officer

David Jachimiak joined ACM as the Chief Information Officer in June of this year. Since that time, he has been focused on a number of major information system projects targeted at enhancing laboratory and clinical trials systems efficiency and information availability. As well, he is committed to aligning IT strategies and resources to be more tightly aligned and responsive to the information needs of Laboratory and Clinical Trials Operations and ACM customers.

Mr. Jachimiak has significant information systems development and process engineering leadership experience in the health industry, having developed and implemented enterprise solutions in the pharmaceuticals, medical device and regenerative medicine verticals for Bristol-Myers Squibb, Bausch and Lomb and LifeNet Health before coming to ACM.
He holds undergraduate degrees in both business and technology, and a Masters in Business Administration from Niagara University.

New and Improved Test Information

Syphilis Reporting Enhancement

Suzanne E. Dale, Ph.D., D(ABMM), Director of Microbiology and Molecular Diagnostics

ACM Medical Laboratory announces an enhancement to our syphilis reports. Previously, physicians received separate reports for the syphilis screening EIA, RPR and TP-PA (if necessary). Often, there was a delay between reporting the EIA / RPR and the TP-PA results. Some of our customers were concerned that this delay resulted in interpretive confusion. We have consolidated all syphilis reporting so that all tests will appear on the same report with an appropriate interpretive comment. Most reports will be issued within 24 hours of sample receipt, however, specimens that require confirmatory testing by TP-PA may take up to 7 days before a final consolidated report is issued.

Women's Health Testing

Suzanne E. Dale, Ph.D., D(ABMM), Director of Microbiology and Molecular Diagnostics

ACM Medical Laboratory now offers a comprehensive menu of molecular assays to detect high-risk (HR) human papillomaviruses (HPV) in ThinPrep PAP specimens. Our test menu is aligned with the most recent guidance issued by the American Cancer Society, American Society for Colposcopy and Cervical Pathology (ASCCP) and the American Society for Clinical Pathology. These organizations have recommended high risk HPV screening in all women between the ages of 30 and 65 when a PAP smear is performed. This screening is often referred to as "co-testing." In addition to co-testing, women with a positive HR-HPV assay may be triaged more effectively for colposcopy with the addition of an HPV 16/18 genotyping assay. Women who are positive for either HPV 16 or HPV 18 are at greater risk for progression to cervical cancer than women who are infected with other genotypes.

ACM Medical Laboratory is pleased to offer the following options for cervical cancer screening:

Test Code	Test Components
0804	ThinPrep pap only
0283	Women under 30: ThinPrep pap with reflex to HR HPV
0280	Women over 30: ThinPrep pap with reflex to HR HPV
0281*	Women over 30: ThinPrep pap with HR HPV with reflex to HPV 16/18 genotyping

*Test code 0281 meets the definition of "co-testing", as defined by the ASCCP.